



Samrat Pharmachem Limited

Manufacturers, Importers & Exporters of Pharmaceutical Chemicals

Regd Office : Plot No. A2/3445, GIDC Phase 4, Ankleshwar 393 002, Gujarat
 Corp Office : 701/702 Business Square, M. A. Road, Andheri-West, Mumbai 400 058
 CIN : L24230GJ1992PLC017820

Statement of Standalone Unaudited Results for the Quarter ended 30 June, 2016

(Rupees in Lakhs)

Particulars	Quarter Ended			Year Ended
	30-Jun-16 (Unaudited)	30-Jun-15 (Unaudited)	31-Mar-16 (Unaudited)	31-Mar-16 (Audited)
1 (a). Net Income from Sales / Services	2,127.48	1,256.56	1,997.36	6,185.52
(b). Other Operating Income	4.29	0.83	3.02	7.69
Total Income	2,131.77	1,257.39	2,000.38	6,193.21
2. Expenditure				
a) Consumption of Raw Materials	1,923.01	1,210.49	1,621.80	5,065.47
b) (Increase)/Decrease in Stock in Trade/WIP	33.26	(67.28)	20.23	(31.42)
c) Purchase of Traded Goods	0.00	0.00	172.27	580.12
d) Employee Costs	22.11	20.25	31.53	97.78
e) Depreciation	11.13	10.84	11.23	44.34
f) Other Expenditure				
(i) Manufacturing Expenses	56.14	48.10	73.20	210.26
(ii) Administration Expenses	13.33	11.64	13.39	57.79
(iii) Selling & Distribution Expenses	21.44	8.32	25.94	85.70
g) Total	2,080.42	1,242.36	1,969.59	6,110.04
3. Profit from Operations before Other Income, Interest and Exceptional Items	51.35	15.03	30.79	83.17
4. Other Income	5.23	2.84	1.56	12.97
5. Profit before Interest and Exceptional items	56.58	17.87	32.35	96.14
6. Interest	17.40	5.88	10.42	50.86
7. Profit after Interest but before Exceptional items	39.18	11.99	21.93	45.28
8. Exceptional Items	0.00	0.00	(0.42)	(0.42)
9. Profit / (Loss) from ordinary activities before tax	39.18	11.99	21.51	44.86
10. Tax expense (incl deferred tax)	14.30	4.82	(3.91)	(14.74)
11. Net Profit / (Loss) from ordinary activities after tax	24.88	7.17	17.60	30.12
12. Extraordinary Items (Net of tax expense)	0.00	0.00	0.00	0.00
13. Net Profit / (Loss) for the period	24.88	7.17	17.60	30.12
14. Paid-up Equity Share Capital (Face Value Rs.10)	308.97	308.97	308.97	308.97
15. Reserves excluding revaluation reserves	1,091.53	1,043.69	1,066.64	1,066.64
16. Earnings per share				
a) Basic and diluted EPS before extraordinary items for the period, year-to-date, previous year	0.81	0.23	0.57	0.97
b) Basic and diluted EPS after extraordinary items for the period, year-to-date, previous year	0.81	0.23	0.57	0.97
17. Public shareholding				
-- Number of shares	1,623,393	1,629,751	1,628,282	1,628,282
-- Percentage of shareholding	52.54	52.75	52.70	52.70
18. Promoters and promoter group shareholding**				
a) Pledged/ Encumbered				
-- Number of shares	0.00	0.00	0.00	0.00
-- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0.00	0.00	0.00	0.00
-- Percentage of shares (as a % of the total share capital of the company)	0.00	0.00	0.00	0.00



Samrat Pharmachem Limited

Manufacturers, Importers & Exporters of Pharmaceutical Chemicals

b) Non-encumbered				
-- Number of shares	1,466,307	1,459,949	1,461,418	1,461,418
-- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
-- Percentage of shares (as a % of the total share capital of the company)	47.46	47.25	47.30	47.30

Notes:

1. The above results were reviewed by the Audit Committee of the Board of Directors.
2. The Statutory Auditors have carried out a limited review of the results for the quarter ended 30 June, 2016
3. The above unaudited results have been taken on record by the Board of Directors at its Meeting held on Friday, 12 August 2016 at the Corporate Office of the Company.
4. Information on investor complaints pursuant to clause 41 of the listing agreement for the quarter ended 30 June, 2016

Opening Balance as on	1-Apr-2016	0
Received during the quarter		0
Disposed of during the quarter		0
Closing Balance as on	30-Jun-2016	0

By order of the Board of Directors
For Samrat Pharmachem Limited

Rajesh Mehta
Executive Director

Place : Mumbai
Date : 12 August 2016



SHAH, SHAH & SHAH (Regd.)

Chartered Accountants


Review Report to
BSE Limited
P. J. Towers, Fort,
Bombay Samachar Marg,
Mumbai - 400023

We have reviewed the accompanying statement of unaudited financial results of **Samrat Pharmachem Limited** for the period ended 30th June 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For SHAH, SHAH & SHAH
CHARTERED ACCOUNTANTS


(Mehul O. Shah)
Partner
Membership No.49361
FRN. : 116457W
Mumbai : August 12, 2016

